| Title |
Biologic therapy for refractory scleritis: a new treatment perspective
|
|---|---|
| Published in |
International Ophthalmology, August 2015
|
| DOI | 10.1007/s10792-015-0124-0 |
| Pubmed ID | |
| Authors |
Tania Sales de Alencar de Fidelix, Luis Antonio Vieira, Denise de Freitas, Virginia Fernandes Moça Trevisani |
| Abstract |
Scleritis is an umbrella term for a heterogeneous group of ocular diseases that can be associated with autoimmune or systemic disorders. The purpose of this article was to review the literature regarding the use of biologic drugs to treat refractory scleritis. A search of the MEDLINE, Embase, and LILACS electronic databases was conducted, and the reference lists of published articles were hand-searched. No language filters were used. This search strategy yielded no randomized trials of the use of biologic therapies to treat scleritis; only case reports and retrospective studies were retrieved. These studies suggest that monoclonal antibodies (infliximab and adalimumab) are superior to the soluble TNF receptor fusion protein etanercept for the treatment of scleritis in patients that do not respond to corticosteroids and/or to immunosuppressive treatment. Rituximab seems to be the best option for scleritis associated with vasculitis. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 1 | 2% |
| Unknown | 58 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 12 | 20% |
| Student > Bachelor | 8 | 14% |
| Other | 8 | 14% |
| Student > Postgraduate | 8 | 14% |
| Student > Ph. D. Student | 5 | 8% |
| Other | 10 | 17% |
| Unknown | 8 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 58% |
| Biochemistry, Genetics and Molecular Biology | 4 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Agricultural and Biological Sciences | 2 | 3% |
| Computer Science | 1 | 2% |
| Other | 6 | 10% |
| Unknown | 10 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 November 2015.
All research outputs
#20,295,501
of 22,832,057 outputs
Outputs from International Ophthalmology
#660
of 1,033 outputs
Outputs of similar age
#224,099
of 266,770 outputs
Outputs of similar age from International Ophthalmology
#8
of 25 outputs
Altmetric has tracked 22,832,057 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,033 research outputs from this source. They receive a mean Attention Score of 2.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,770 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.